Citigroup Inc Caladrius Biosciences, Inc. Transaction History

Citigroup Inc

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 10, 2022	SELL	$0.41 - $0.74 $1,845 - $3,330	-4,500 Reduced 99.96%	2 $0
Q1 2022 May 12, 2022	BUY	$0.63 - $1.03 $2,835 - $4,635	4,500 Added 225000.0%	4,502 $3,000
Q3 2021 Nov 10, 2021	BUY	$1.15 - $1.57 $2 - $3	2 New	2 $0

Ticker CLBS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,583,200
Market Cap $25.8M
Description
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical li...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.